InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
- InMed Pharmaceuticals Inc. closed the calendar year 2023 with a cash position of US$9.5 million.
- The commercial BayMedica subsidiary experienced a remarkable 164% revenue growth.
- The Company launched two new preclinical programs focusing on Alzheimer's disease and Age-Related Macular Degeneration.
- INM-901 shows promising results in targeting biological pathways associated with Alzheimer's, while INM-089 demonstrates potential in preserving retinal function.
- The Company is seeking partnerships for the further development of INM-755 in the treatment of chronic itch and related ailments.
- None.
Insights
The reported 164% revenue growth in InMed Pharmaceuticals' commercial subsidiary BayMedica is a significant indicator of the company's expanding market presence and operational success. This growth figure surpasses typical industry benchmarks, which often hover around single to low double-digit percentages for mature industries. However, for the biotech and pharmaceutical sector, particularly in niche markets such as rare cannabinoids, higher growth rates can be expected due to rapid innovation and market adoption.
BayMedica's revenue increase from $1.2 million, coupled with a 37% quarter-over-quarter growth, suggests a strong upward trajectory that investors may view favorably, potentially leading to positive stock market performance. The cash position of over $9.5 million provides the company with a solid foundation to pursue further development milestones and could be a buffer against operational risks, such as delays in clinical trials or unexpected regulatory hurdles.
Advancement in preclinical programs for Alzheimer's and Age-Related Macular Degeneration (AMD) represents a strategic move into high-need therapeutic areas. Alzheimer's and AMD are both diseases with significant unmet medical needs and potential treatments could tap into large market opportunities. The multimodal approach of INM-901 targeting neuroprotection, neuroinflammation and neuronal function suggests a comprehensive strategy that may differentiate it from other treatments in development.
Furthermore, INM-089's focus on retinal function and cell protection in AMD could address a critical aspect of disease progression. The anticipated filing of an IND application in the first half of 2025 for INM-089 indicates a clear pathway towards clinical development. These programs, if successful, could lead to substantial long-term value creation for the company and its stakeholders.
The demand for rare cannabinoids is indicative of a growing trend within the pharmaceutical and supplement industries. As InMed Pharmaceuticals focuses on these niche areas, it positions itself advantageously within a market that is expected to expand as research uncovers new therapeutic uses for cannabinoids. The company's emphasis on proprietary small molecule drug development could provide competitive advantages through patent protections and unique product offerings.
However, it is important to note that the pharmaceutical development process is fraught with risks, including failure in clinical trials and regulatory challenges. The success of the company's preclinical and clinical programs will be critical in determining its future financial health and stock market valuation.
- Advancing two new preclinical programs in Alzheimer's and Age-Related Macular Degeneration
- Closed calendar year 2023 with cash position of US
$9.5 million 164% revenue growth in the commercial BayMedica subsidiary
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today reports financial results for the second quarter of the fiscal year 2024 which ended December 31, 2023.
The Company's full financial statements and related MD&A for the second quarter ended December 31, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
Eric A. Adams, InMed Chief Executive Officer, commented, "This period was another strong operational quarter for the Company, as we expanded our pharmaceutical pipeline with the launch of two new programs with a particular focus on proprietary small molecule drug development candidates. As outlined in our 2024 business update last month, we have further accelerated our development efforts in both INM-901 as a potential multimodal treatment option for Alzheimer's disease and INM-089 in the treatment of Age-related Macular Degeneration." Adams continued, "Our commercial subsidiary, BayMedica LLC, continues to grow revenues, up
Business Update
Pharmaceutical Development Programs
INM-901 in treatment of Alzheimer's disease:
Following the launch of INM-901 in October 2023, the next stages of longer-term preclinical studies are underway in a robust preclinical disease model and will be followed by studies of drug distribution, metabolism (elimination of the drug from the body), pharmacokinetics (how the body interacts with the administered drug) and continuation of pharmaceutical drug development activities such as manufacturing and formulation.
Based on early in vitro research, INM-901 showed potential to target several biological pathways associated with Alzheimer's, including neuroprotection of the brain neurons from beta-amyloid peptide-induced toxicity, a reduction in neuroinflammation and targeting neuronal function improvement via extension of neurite length. In addition to these encouraging in vitro testing outcomes, INM-901 demonstrated favorable results in an in vivo preclinical Alzheimer's proof-of-concept model. When compared to the placebo treated Alzheimer's disease group in these preclinical studies, INM-901 treatment groups demonstrated a trend towards improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness.
INM-089 in the treatment of AMD
The Company is currently engaged in API and drug product formulation work and expects to initiate Investigational New Drug ("IND")-enabling studies in mid-2024, with the anticipation of filing an IND application with regulatory authorities in calendar 1H 2025.
INM-089 preclinical research has shown promising results in preserving retinal function, proactively protecting retinal cells, and enhancing the thickness of the outer nuclear layer of the retina where photoreceptors are located.
INM-755: Assessing partnership opportunities
The comprehensive data and findings from the Phase 2 clinical trial will soon be available on the National Institutes of Health ("NIH") clinicaltrials.gov website and the European Union Clinical Trials Register website. Additionally, an abstract will soon be published in Itch, the official journal of the International Forum for the Study of Itch.
The Company believes that INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments. The Company is currently seeking partnerships for continued development. For further details see press release date June 22, 2023.
BayMedica Commercial Subsidiary
BayMedica revenues continue to trend positively with
Financing Activities and Results of Operations (expressed in US Dollars):
On October 26, 2023, the Company closed a Private Placement and Preferred Investment Option Exercise financing, for gross proceeds of
For the six months ended December 31, 2023, the Company recorded a net loss of
Research and development and patents expenses were
The Company incurred general and administrative expenses of
At December 31, 2023, the Company's total issued and outstanding shares were 5,667,970. Subsequent to quarter end, 391,000 shares held in abeyance were issued to investors from the October 2023 financing activities. As of the date of these filings, the issued and outstanding shares are 6,058,970. During the three and six months ending December 31, 2023, the weighted average number of common shares was 7,973,465 and 5,650,828, which is used for the calculation of loss per share for the respective interim periods.
At December 31, 2023, the Company's cash, cash equivalents and short-term investments were
Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure requirements into the third quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues from the sale of products in the Health & Wellness sector as well as the level and timing of our operating expenses.
| Table 1. CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS | ||||||
| Expressed in U.S. Dollars | ||||||
| December 31, | June 30, | |||||
| 2023 | 2023 | |||||
| (unaudited) | ||||||
| ASSETS | $ | $ | ||||
| Current | ||||||
| Cash and cash equivalents | 9,534,922 | 8,912,517 | ||||
| Short-term investments | 44,462 | 44,422 | ||||
| Accounts receivable, net | 372,869 | 260,399 | ||||
| Inventories | 744,839 | 1,616,356 | ||||
| Prepaids and other current assets | 1,112,977 | 498,033 | ||||
| Total current assets | 11,810,070 | 11,331,727 | ||||
| Non-Current | ||||||
| Property, equipment and ROU assets, net | 1,481,102 | 723,426 | ||||
| Intangible assets, net | 1,864,292 | 1,946,279 | ||||
| Other assets | 100,000 | 104,908 | ||||
| Total Assets | 15,255,464 | 14,106,340 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| Current | ||||||
| Accounts payable and accrued liabilities | 1,287,623 | 1,608,735 | ||||
| Current portion of lease obligations | 364,190 | 375,713 | ||||
| Deferred rent | 28,656 | 16,171 | ||||
| Total current liabilities | 1,680,469 | 2,000,619 | ||||
| Non-current | ||||||
| Lease obligations, net of current portion | 802,784 | 15,994 | ||||
| Total Liabilities | 2,483,253 | 2,016,613 | ||||
| Shareholders' Equity | ||||||
| Common shares, no par value, unlimited authorized shares: | ||||||
| 3,328,191 (June 30, 2023 - 3,328,191) issued and outstanding | 79,936,633 | 77,620,252 | ||||
| Additional paid-in capital | 38,122,231 | 35,741,115 | ||||
| Accumulated deficit | (105,415,222 | ) | (101,400,209 | ) | ||
| Accumulated other comprehensive income | 128,569 | 128,569 | ||||
| Total Shareholders' Equity | 12,772,211 | 12,089,727 | ||||
| Total Liabilities and Shareholders' Equity | 15,255,464 | 14,106,340 |
| Table 2: CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited) | ||||||||||||
| Expressed in U.S. Dollars | ||||||||||||
| For the Three Months Ended | For the Six Months Ended | |||||||||||
| December 31 | December 31 | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| $ | $ | $ | $ | |||||||||
| Sales | 1,240,200 | 469,783 | 2,142,062 | 790,571 | ||||||||
| Cost of sales | 745,584 | 338,620 | 1,533,274 | 573,654 | ||||||||
| Inventory write-down | 170,474 | - | 263,404 | 576,772 | ||||||||
| Gross profit | 324,142 | 131,163 | 345,384 | (359,855 | ) | |||||||
| Operating Expenses | ||||||||||||
| Research and development and patents | 609,791 | 851,356 | 1,901,884 | 2,230,009 | ||||||||
| General and administrative | 1,363,958 | 1,464,879 | 2,662,689 | 3,025,356 | ||||||||
| Amortization and depreciation | 55,234 | 49,049 | 110,066 | 98,097 | ||||||||
| Foreign exchange loss | (59,896 | ) | (20,237 | ) | (11,439 | ) | 76,554 | |||||
| Total operating expenses | 1,969,087 | 2,345,047 | 4,663,200 | 5,430,016 | ||||||||
| Other Income (Expense) | ||||||||||||
| Interest and other income | 166,760 | 115,797 | 302,803 | 188,384 | ||||||||
| Loss before income taxes | (1,478,185 | ) | (2,098,087 | ) | (4,015,013 | ) | (5,601,487 | ) | ||||
| Tax expense | - | (3,000 | ) | - | (9,800 | ) | ||||||
| Net loss for the period | (1,478,185 | ) | (2,101,087 | ) | (4,015,013 | ) | (5,611,287 | ) | ||||
| Net loss per share for the period | ||||||||||||
| Basic and diluted | (0.19 | ) | (0.91 | ) | (0.71 | ) | (3.54 | ) | ||||
| Weighted average outstanding common shares | ||||||||||||
| Basic and diluted | 7,973,465 | 2,300,526 | 5,650,828 | 1,583,073 | ||||||||
| Table 3: CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited) | ||||||
| For the six months ended December 31, 2023 and 2022 | ||||||
| Expressed in U.S. Dollars | ||||||
| 2023 | 2022 | |||||
| Cash provided by (used in): | $ | $ | ||||
| Operating Activities | ||||||
| Net loss | (4,015,013 | ) | (5,611,287 | ) | ||
| Items not requiring cash: | ||||||
| Amortization and depreciation | 110,066 | 98,097 | ||||
| Share-based compensation | 43,455 | 187,318 | ||||
| Amortization of right-of-use assets | 191,909 | 197,767 | ||||
| Interest income received on short-term investments | (1,019 | ) | (418 | ) | ||
| Unrealized foreign exchange loss | 978 | 2,167 | ||||
| Inventory write-down | 263,404 | 576,772 | ||||
| Bad debts | - | 25,085 | ||||
| Changes in operating assets and liabilities: | ||||||
| Inventories | 608,113 | 300,576 | ||||
| Prepaids and other currents assets | (614,944 | ) | (29,706 | ) | ||
| Other non-current assets | 4,908 | 5,507 | ||||
| Accounts receivable | (112,470 | ) | (18,705 | ) | ||
| Accounts payable and accrued liabilities | (321,109 | ) | (508,871 | ) | ||
| Deferred rent | 12,485 | 16,171 | ||||
| Lease obligations | (193,109 | ) | (209,112 | ) | ||
| Total cash used in operating activities | (4,022,346 | ) | (4,968,639 | ) | ||
| Investing Activities | ||||||
| Payment of acquisition consideration | - | (500,000 | ) | |||
| Sale of short-term investments | 21,317 | - | ||||
| Purchase of short-term investments | (21,317 | ) | - | |||
| Purchase of property and equipment | (9,291 | ) | - | |||
| Total cash (used in) provided by investing activities | (9,291 | ) | (500,000 | ) | ||
| Financing Activities | ||||||
| Proceeds from private placement net of issuance costs | 4,654,042 | 10,744,351 | ||||
| Total cash provided by financing activities | 4,654,042 | 10,744,351 | ||||
| Increase in cash during the period | 622,405 | 5,275,712 | ||||
| Cash and cash equivalents beginning of the period | 8,912,517 | 6,176,866 | ||||
| Cash and cash equivalents end of the period | 9,534,922 | 11,452,578 | ||||
| SUPPLEMENTARY CASH FLOW INFORMATION: | ||||||
| Cash Paid During the Year for: | ||||||
| Income taxes | $ | - | $ | 9,800 | ||
| Interest | $ | - | $ | - | ||
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||
| Fair value of warrant modification recorded as equity issuance costs | $ | 3,508,749 | $ | - | ||
| Preferred investment options to its placement agent | $ | 325,699 | $ | 691,483 | ||
| Recognition of Right-of-use asset and corresponding operating lease liability | $ | 968,376 | $ | - | ||
About InMed:
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: INM-901 representing a unique and innovative treatment approach compared to current options available to patients; cash runway into calendar 3Q 2024; next stages of advanced preclinical studies of INM-901, including drug metabolism and pharmacokinetics as well as the initiation of pharmaceutical drug development activities such as manufacturing and formulation; disease-modifying effects in an Alzheimer's disease treatment model; and the next stage of studies which may show how the cannabinoid analog INM-901 can improve neuronal function; assessing potential partnership opportunities for the advancement of INM-755; anticipating sustained volume growth over a 12-month period; improving margins over time; being a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/197603
FAQ
What was InMed Pharmaceuticals Inc.'s cash position at the end of calendar year 2023?
By what percentage did the BayMedica subsidiary's revenue grow for the three months ended December 31, 2023?
What are the focus areas of the two new preclinical programs launched by InMed Pharmaceuticals Inc.?
What promising results did INM-901 show in the treatment of Alzheimer's disease?
What positive outcomes were observed in INM-089 preclinical research for the treatment of AMD?
What is the Company seeking for the further development of INM-755?
